An Introduction to Asthma
Asthma is a common and potentially life-threatening chronic inflammatory airway disease. Despite many therapeutic advances, it remains underdiagnosed and undertreated. The mainstay of therapy is maintenance controller therapy such as inhaled corticosteroids, together with separate short-acting β2-agonists for acute symptom relief, but treatment adherence is a major challenge. The heterogeneity of asthma makes it difficult to identify specific therapeutic targets. For patients with specific subtypes of severe asthma, such as eosinophilic asthma, targeted therapies including omalizumab, mepolizumab, reslizumab, benralizumab and dupilumab, can reduce exacerbation rates and improve disease control. As experience with biological therapies increases, they are expected to play a more prominent role in treatment strategies, and novel therapeutic targets such as semaphorins and RhoA/Rho‐kinase, are being investigated.
Browse our selection of video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and a selection of peer-reviewed articles from the journal portfolio.
Our supporting partners do not constitute an endorsement of the content on this page.
Air pollution and respiratory diseases: Claudia Traidl-Hoffmann, EAACI 2023
Air pollution has been linked to exacerbating and causing symptoms associated with respiratory diseases, particularly impacting patients with asthma, COPD and allergic disease. touchRESPIRATORY were delighted to speak with Prof. Claudia Traidl-Hoffmann (University in Augsburg, Germany) around the symptoms associated with exposure to air pollution, the impact of air pollution on existing respiratory conditions and […]
The Effect of Lebrikizumab on Inflammatory Biomarkers in Patients with Asthma
touchREVIEWS in Respiratory & Pulmonary Diseases. 2023;8(1):2–5 DOI: https://doi.org/10.17925/USRPD.2023.8.1.2
Asthma is a heterogeneous disease with notable variation in its clinical course and response to treatment. Despite management with standard-of-care therapies, a proportion of patients remain uncontrolled and at risk of life-threatening exacerbations and disease worsening. Advances in understanding the heterogeneity of asthma have helped to identify patients who will benefit from an understanding of […]
Foreword touchREVIEWS in Respiratory & Pulmonary Diseases Volume 8, Issue 1, 2023
touchREVIEWS in Respiratory & Pulmonary Diseases. 2023;8(1):1
Welcome to the latest issue of touchREVIEWS in Respiratory & Pulmonary Diseases, in which we bring you a range of topical and timely articles in the field of lung diseases. In this issue, we begin with an expert interview about lebrikizumab (an anti-interleukin-13 biologic) for asthma. Stanley Szefler describes the clinical trials that have helped […]
Treatment strategies for metabolic perturbations in obesity-related asthma: Anne E. Dixon, ATS 2023
Recent epidemiological studies have shown that treatments for obesity-mediated metabolic perturbations such as GLP-1 receptors might improve symptoms in obesity-related asthma. We were delighted to speak to Prof. Anne E. Dixon (University of Vermont Larner College of Medicine, Burlington, VT, USA) around the treatment strategies associated with obesity-mediated metabolic perturbations, the data surrounding weight loss as […]
Diagnosis, management and pathophysiology of obesity-related asthma: Anne E. Dixon, ATS 2023
Obesity-related asthma is associated with poorer control and a greater number of exacerbations of asthma, which in turn reduces patient quality-of-life. We were delighted to speak to Prof. Anne E. Dixon (University of Vermont Larner College of Medicine, Burlington, VT, USA) around the difficulties in the diagnosis and management of obese asthma, the association between […]
Isaac Schmale, AAAAI 2023: Efficacy of dupilumab for nasal polyposis in patients with aspirin-exacerbated respiratory disease
Dupilumab is used to manage chronic rhinosinusitis with nasal polyposis, however there is limited data regarding its use in patients with aspirin-exacerbated respiratory disease (AERD). touchRESPIRATORY caught up with Dr Isaac Schmale (University of Rochester Medical Center, Rochester, NY, USA) around the aims, eligibility, methodology and findings of his study investigating the real-world outcomes of […]
Isaac Schmale, AAAAI 2023: Signs and symptoms of aspirin-exacerbated respiratory disease and its treatment paradigm
touchRESPIRATORY were delighted to speak with Dr Isaac Schmale (University of Rochester Medical Center, Rochester, NY, USA) around the signs and symptoms of aspirin-exacerbated respiratory disease (AERD), the incidence of AERD in people with asthma, the current treatment paradigm for AERD and the unmet needs in its treatment. The abstract ‘Real-world Outcomes of Dupilumab Therapy […]
Ronald Strauss, AAAAI 2023: Hot topics to explore in the field of respiratory medicine
touchRESPIRATORY were delighted to speak with a valued member of our Editorial Board for touchREVIEWS in Respiratory & Pulmonary Diseases, Dr Ronald Strauss (Case Western Reserve University; Cleveland Allergy and Asthma Center, Cleveland, OH, USA), about the areas in the field of respiratory medicine that he is most looking forward to exploring in 2023. Questions […]
Ronald Strauss, AAAAI 2023: Efficacy of mepolizumab in patients with severe eosinophilic asthma
Mepolizumab is a humanized monoclonal antibody used to treat severe eosinophilic asthma. We caught up with Dr Ronald Strauss (Case Western Reserve University; Cleveland Allergy and Asthma Center, Cleveland, OH, USA), a valued member of our Editorial Board for touchREVIEWS in Respiratory & Pulmonary Diseases, to discuss the rationale, findings and clinical significance of his […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!